Literature DB >> 31281627

Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines.

Jorn C Goet1, Gideon M Hirschfield2.   

Abstract

New guidelines have been produced for the management of primary biliary cholangitis, an infrequent but nonetheless important autoimmune liver disease. We provide a succient commentary and overview of the key features of disease management that arise from these recent guideline recommendations, with a focus on therapy with licensed agents (ursodeoxycholic acid and obeticholic acid) as well as personalised management of disease complications and associated symptoms.

Entities:  

Keywords:  cholestasis; obeticholic acid; primary biliary cirrhosis; ursodeoxycholic acid

Year:  2019        PMID： 31281627      PMCID： PMC6583568          DOI： 10.1136/flgastro-2018-101109

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


  11 in total

1.  Biomarkers and surrogate endpoints in clinical trials.

Authors:  Thomas R Fleming; John H Powers
Journal:  Stat Med       Date:  2012-06-18       Impact factor: 2.373

2.  Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.

Authors:  Teru Kumagi; Maha Guindi; Sandra E Fischer; Tamara Arenovich; Rupert Abdalian; Catalina Coltescu; E Jenny Heathcote; Gideon M Hirschfield
Journal:  Am J Gastroenterol       Date:  2010-05-25       Impact factor: 10.864

3.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

4.  A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Authors:  Christophe Corpechot; Olivier Chazouillères; Alexandra Rousseau; Antonia Le Gruyer; François Habersetzer; Philippe Mathurin; Odile Goria; Pascal Potier; Anne Minello; Christine Silvain; Armand Abergel; Maryline Debette-Gratien; Dominique Larrey; Olivier Roux; Jean-Pierre Bronowicki; Jérôme Boursier; Victor de Ledinghen; Alexandra Heurgue-Berlot; Eric Nguyen-Khac; Fabien Zoulim; Isabelle Ollivier-Hourmand; Jean-Pierre Zarski; Gisèle Nkontchou; Sara Lemoinne; Lydie Humbert; Dominique Rainteau; Guillaume Lefèvre; Luc de Chaisemartin; Sylvie Chollet-Martin; Farid Gaouar; Farid-Hakeem Admane; Tabassome Simon; Raoul Poupon
Journal:  N Engl J Med       Date:  2018-06-07       Impact factor: 91.245

5.  Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.

Authors:  Christophe Corpechot; Fabrice Carrat; Raoul Poupon; Renee-Eugenie Poupon
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

6.  Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Authors:  Willem J Lammers; Gideon M Hirschfield; Christophe Corpechot; Frederik Nevens; Keith D Lindor; Harry L A Janssen; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; Pietro Invernizzi; Pier M Battezzati; Albert Parés; Andrew K Burroughs; Andrew L Mason; Kris V Kowdley; Teru Kumagi; Maren H Harms; Palak J Trivedi; Raoul Poupon; Angela Cheung; Ana Lleo; Llorenç Caballeria; Bettina E Hansen; Henk R van Buuren
Journal:  Gastroenterology       Date:  2015-08-07       Impact factor: 22.682

7.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

8.  No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England.

Authors:  Richard J Q McNally; Peter W James; Samantha Ducker; Paul D Norman; Oliver F W James
Journal:  Am J Epidemiol       Date:  2014-01-08       Impact factor: 4.897

9.  The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.

Authors:  Marco Carbone; Stephen J Sharp; Steve Flack; Dimitrios Paximadas; Kelly Spiess; Carolyn Adgey; Laura Griffiths; Reyna Lim; Paul Trembling; Kate Williamson; Nick J Wareham; Mark Aldersley; Andrew Bathgate; Andrew K Burroughs; Michael A Heneghan; James M Neuberger; Douglas Thorburn; Gideon M Hirschfield; Heather J Cordell; Graeme J Alexander; David E J Jones; Richard N Sandford; George F Mells
Journal:  Hepatology       Date:  2015-10-20       Impact factor: 17.425

10.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

Authors:  Willem J Lammers; Henk R van Buuren; Gideon M Hirschfield; Harry L A Janssen; Pietro Invernizzi; Andrew L Mason; Cyriel Y Ponsioen; Annarosa Floreani; Christophe Corpechot; Marlyn J Mayo; Pier M Battezzati; Albert Parés; Frederik Nevens; Andrew K Burroughs; Kris V Kowdley; Palak J Trivedi; Teru Kumagi; Angela Cheung; Ana Lleo; Mohamad H Imam; Kirsten Boonstra; Nora Cazzagon; Irene Franceschet; Raoul Poupon; Llorenç Caballeria; Giulia Pieri; Pushpjeet S Kanwar; Keith D Lindor; Bettina E Hansen
Journal:  Gastroenterology       Date:  2014-08-23       Impact factor: 22.682
View more
  1 in total

1.  Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids.

Authors:  Gregory R Young; Tarek M Abdelghany; Alistair C Leitch; Michael P Dunn; Peter G Blain; Clare Lanyon; Matthew C Wright
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.